{"TopicDetails": {"type": 0, "ccm2Id": 45928853, "cftId": 0, "identifier": "HORIZON-JU-GH-EDCTP3-2023-02-02-two-stage", "title": "Advancing point-of-care diagnostics to the market", "publicationDateLong": 1681430400000, "callIdentifier": "HORIZON-JU-GH-EDCTP3-2023-02-two-stage", "callTitle": "Research and Innovation actions supporting the global health EDCTP3 Joint Undertaking", "callccm2Id": 45928946, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "topicMGAs": [], "tags": ["point of care", "SME", "clinical research", "edctp3", "regulatory sciences", "Africa", "diagnostic", "antimicrobial resistance", "clinical trials", "global health", "edctp", "Small and Medium-sized Enterprise", "sub-Saharan Africa", "infectious diseases", "health", "healthcare system"], "keywords": ["Diagnostics", "Africa", "Global health", "Clinical research", "Societal Engagement", "International Cooperation", "Healthcare system", "Public health", "Clinical trials", "Diagnostic technology", "Social sciences and humanities", "Infectious diseases", "Regulatory affairs"], "flags": ["Africa", "SocietalEngagement", "EC-WORLD", "SSH"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "27 June 2023", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["28 September 2023", "03 April 2024"]}], "latestInfos": [{"approvalDate": "Dec 20, 2023 3:21:27 PM", "lastChangeDate": "Dec 20, 2023 3:21:27 PM", "content": "<p><u><strong>EVALUATION RESULTS STAGE 1</strong></u></p>\r\n<div>Published: 14/04/23&nbsp;</div>\r\n<div>Deadline: 28/09/23</div>\r\n<div>Available budget: 56.000.000EUR</div>\r\n<div>&nbsp;</div>\r\n<div>In accordance with the call conditions, the evaluation of the first-stage proposals was made looking only at the criteria 'Excellence' and 'Impact'. The threshold for both criteria was 4. The overall threshold (applying to the sum of the two individual scores) was set for each topic/type of action with separate call-budget-split at a level that allowed the total requested budget of proposals admitted to stage 2 be as close as possible to 3 times the available budget (and not below 2.5 times the budget):</div>\r\n<ul>\r\n    <li>HORIZON-JU-GH-EDCTP3-2023-02-01-two-stage:&nbsp;<strong>8</strong>&nbsp;points</li>\r\n    <li>HORIZON-JU-GH-EDCTP3-2023-02-02-two-stage:&nbsp;<strong>9</strong>&nbsp;points</li>\r\n</ul>\r\n<div>The results of the evaluation of this call are as follows :&nbsp;</div>\r\n<ul>\r\n    <li>Number of proposals submitted (including proposals transferred from or to other calls): 79</li>\r\n    <li>Number of ineligible proposals: 5</li>\r\n    <li>Number of above-threshold proposals: 37</li>\r\n    <li>Total budget requested for above-threshold proposals: 180.986.064</li>\r\n</ul>\r\n<div>We recently informed the applicants about the evaluation results for their proposals.&nbsp;</div>\r\n<div>For questions, please contact EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu</div>"}], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3544965": [{"action": "HORIZON-JU-GH-EDCTP3-2023-02-01-two-stage - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "27 June 2023", "deadlineModel": "two-stage", "deadlineDates": ["28 September 2023", "03 April 2024"], "budgetYearMap": {"2023": 30000000}, "expectedGrants": 6, "minContribution": 5000000, "maxContribution": 5000000, "budgetTopicActionMap": {}}], "3544967": [{"action": "HORIZON-JU-GH-EDCTP3-2023-02-02-two-stage - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "27 June 2023", "deadlineModel": "two-stage", "deadlineDates": ["28 September 2023", "03 April 2024"], "budgetYearMap": {"2023": 26000000}, "expectedGrants": 5, "minContribution": 5000000, "maxContribution": 5000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2023"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>Proposal under this topic should aim to deliver results that are directed, tailored towards, and contributing to all of the following expected outcomes:</p><ul level=\"0\"><li>Health care providers and professionals have access to novel or improved point-of-care diagnostic (POC) devices that are suited to rapidly detect infectious diseases of relevance in sub-Saharan Africa (SSA) and within the scope of the Global Health EDCTP3 Scientific Research and Innovation Agenda.</li><li>A diverse and robust pipeline of in vitro diagnostics is available, increasing options for clinical deployment, also in case of an infectious diseases outbreak with epidemic or pandemic potential, that can reach the most vulnerable populations.</li><li>Health authorities and health care systems have access to health data and evidence to better develop and implement informed health policies and improved clinical surveillance of infectious diseases in SSA.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>POC diagnostic tests that are easy to use, affordable and can rapidly diagnose diseases will lead to more timely treatment and thereby reduce mortality, morbidity, and transmission of diseases. POC diagnostic tests should improve the quality of healthcare for resource-poor communities in developing countries, where the burden of disease is the highest. A diagnostics gap for many diseases affecting SSA still exists and needs to be closed urgently to contribute the global and national disease elimination targets.</p><p>Hence, proposals submitted under this topic should implement clinical studies that lead to market authorisation of the relevant POC diagnostic test. The POC diagnostic test device should be aimed at detection of diseases that currently lack POC diagnosis tests or where POC diagnostics are inadequate. Tests that can in the same specimen simultaneously and rapidly detect and thereby distinguish a wide range of diseases for improved clinical decision-making are encouraged (e.g., distinction between bacterial versus viral pathogens). The POC diagnostic tools are expected to be affordable and suitable for use in SSA countries. POC diagnostics for all diseases in scope of the current Global Health EDCTP3 programme<sup>[1]</sup>, for example antimicrobial resistance and emerging diseases, are included in this call (exception is Ebola Virus disease, covered under topic HORIZON-JU-GH-EDCTP3-2023-01-04).</p><p>Proposals should address <strong>all</strong> of the following areas:</p><ul level=\"0\"><li>Clinical performance studies in several sites across SSA of POC diagnostics that are of high technology readiness level to achieve regulatory approval and market launch (i.e., CE mark); post-market surveillance studies are excluded from this call and are covered by other initiatives such as the African Health Diagnostics Platform<sup>[2]</sup>;</li><li>Studies need to provide evidence-based practice for the POC diagnostic test especially in terms of the ability to decide on treatment options after diagnosis and improving disease outcome; the possibility of the POC diagnostic to be deployed in the field, its usability by primary care and community health care workers in resource-limited patient communities should be especially considered;</li><li>Inclusion of a clear regulatory path to market to ensure future compliance with the legal requirements; early engagement with regulatory authorities is expected;</li><li>Product development plans for translation from prototype to industrial design, to implementation and sustainability of the innovation should be provided, also including a plan for the process of \u201csample to result to the use of result &amp; treatment option\u201d and how to report data &amp; results (e.g., via mobile health/portable technology);</li><li>Where available and relevant, World Health Organization target product profiles for diagnostics need to be addressed<sup>[3]</sup>;</li><li>Involvement of industry, notably of small and medium-sized enterprises (SMEs), especially African SMEs, is expected. Involvement of African SMEs is highly encouraged to contribute to developing the African industry and access to health products.<sup>[4]</sup></li> </ul><p>Proposals submitted under this topic are encouraged to consider innovative diagnostics sampling methods or samples bringing a significant improvement, such as less invasive sampling methods and self-testing at home. The POC diagnostic should allow for easy storage, such as at room temperature. Consideration of environmental friendliness of diagnostic tests would be advantageous. Transmission and economic modelling to examine the impact of the POC diagnostic assay on performance of long-term health outcomes and cost-effectiveness could be envisioned. Relevant partnerships with local and international organisation to create solutions for improved deployment of diagnostics for vulnerable populations in low-resource settings could be sought.</p><p>In addition, where relevant, the link between the diagnostic devices to relevant infectious disease surveillance strategies to inform public health authorities and advise public health policies should be made. This can include monitoring the impact of relevant POCs on the use of antibiotics.</p><p>For all proposed research activities, attention should be paid to critical social factors such as sex, gender, age, socio-economic factors, ethnicity/migration, and disability. Populations for POC diagnostic test development and evaluation of the POC diagnostic test performance and appropriateness should also include vulnerable populations, including children, pregnant women, people with co-infections and co-morbidities, older people, and people living in hard-to-reach communities. Rapid feedback from end-users through community engagement on the performance and acceptance of the technologies and their most effective use in endemic settings is expected.</p><p>Applicants need to concisely describe any prior research findings and explain how the proposal builds on these results. Building on relevant results from projects supported under previous EDCTP programmes is encouraged.</p><p>Proposals are expected to come from research consortia with a strong representation of institutions and researchers from African countries, including involvement of franco/lusophone countries where possible and relevant.</p><p>All projects funded under this topic are strongly encouraged to participate in networking and joint activities, as appropriate. These networking and joint activities could, for example, involve the participation in joint workshops, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Therefore, proposals are expected to include a budget for the attendance to regular joint meetings and may consider covering the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase. In this regard, the Global Health EDCTP3 Joint Undertaking may take on the role of facilitator for networking and exchanges, including with relevant stakeholders, if appropriate.</p><p>[1]<a href=\"http://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf\">https://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf</a></p><p>[2]<a href=\"https://www.eib.org/en/projects/pipelines/all/20190551\">AHDP - AFRICAN HEALTH DIAGNOSTICS PLATFORM (eib.org)</a></p><p>[3]The list of target product profiles that have been developed by the World Health Organization can be accessed at: <a href=\"https://www.who.int/observatories/global-observatory-on-health-research-and-development/analyses-and-syntheses/target-product-profile/links-to-who-tpps-and-ppcs\">https://www.who.int/observatories/global-observatory-on-health-research-and-development/analyses-and-syntheses/target-product-profile/links-to-who-tpps-and-ppcs</a>; please note that this list includes target product profiles for different types of healthcare interventions.</p><p>[4]The Team Europe initiative (TEI) on Manufacturing and Access to Vaccines, Medicines, and Health Technologies (MAV+) <a href=\"http://europa.eu/capacity4dev/tei-jp-tracker/tei/manufacturing-and-access-vaccines-medicines-and-health-technology-products-africa\">https://europa.eu/capacity4dev/tei-jp-tracker/tei/manufacturing-and-access-vaccines-medicines-and-health-technology-products-africa</a></p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p><u>Expected impacts of the calls under the 2023 work programme of the Global Health EDCTP3 JU</u></p><p>Activities funded under the 2023 calls for proposals should contribute to:</p><ul level=\"0\"><li>Achieve SDG3 \u2018Ensure healthy lives and promote well-being for all at all ages\u2019 in sub-Saharan African countries;</li><li>Enable the implementation of the short and medium term actions foreseen by the AU EU Innovation Agenda<sup>[1] </sup>(expected to be adopted in June 2023) in the area of Public Health</li><li>Provide evidence for informed health policies and guidelines within public health systems in sub-Saharan Africa and at international level;</li><li>Strengthen clinical research capability in sub-Saharan Africa to rapidly respond to emerging epidemics;</li><li>Enable a regulatory environment that can ensure effective development, delivery, and uptake of new or improved safe health technologies guaranteeing that trials in sub-Saharan African countries meet international standards;</li><li>Increase cost effectiveness of public investment through collaboration of funders of clinical trials in the area of infectious diseases in sub-Saharan Africa;</li><li>Strengthen health systems to ensure uptake of effective health technologies and innovations;</li><li>Enhance sustainable global scientific collaboration in health research and international cooperation across sub-Saharan Africa.</li><li>Improve opportunities for training of researchers and healthcare professionals in sub-Saharan Africa.</li> </ul><p><sup>[1]</sup>Working document of the AU EU Innovation Agenda available online at: <a href=\"http://research-and-innovation.ec.europa.eu/system/files/2022-02/final_au-eu_ia_14_february.pdf\">https://research-and-innovation.ec.europa.eu/system/files/2022-02/final_au-eu_ia_14_february.pdf</a></p>\n", "conditions": "<h1><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\">General conditions</span></b></span></span></span></h1>\r\n<p class=\"MsoNormal\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\">described in </span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex A</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">and </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex E</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Horizon Europe Work Programme General Annexes</span></span></span></p>\n<p style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\"> described in Part B of the Application Form available in the Submission System</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">2. Eligible countries:&nbsp;</span></b></span></span></span></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">The conditions are described in General Annex B except for the specific conditions for GH EDCTP3 funding as regards&nbsp;<u>Entities eligible for funding</u>&nbsp;and&nbsp;<u>Consortium composition,</u>&nbsp;the specific issue of&nbsp;<u>legal entities from which countries can be the coordinator</u>&nbsp;and the obligation to designate a&nbsp;<u>scientific project leader</u>. Participation conditions related to Russia&rsquo;s illegal invasion of Ukraine are also set out below.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><u>Replacing relevant sections in General Annex B to the Horizon Europe work programmes on Eligibility</u></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><em><u>Entities eligible to participate</u></em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, the currently context does not allow the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine. Therefore, such legal entities are not eligible to participate in any capacity. This criterion also applies in cases where the action involves financial support given by grant beneficiaries to third parties established in Russia, Belarus or in non-government-controlled territories of Ukraine (in accordance with Article 204 of the Financial Regulation No 2018/1046).</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">To be eligible for funding, applicants must be established in one of the following countries:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>The Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden;</li>\r\n    <li>The Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Cura&ccedil;&atilde;o (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barth&eacute;lemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR);</li>\r\n    <li>Countries associated to Horizon Europe<sup>[1]</sup>; Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo<sup>[2]</sup>, Moldova, Montenegro, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine. Considering the Union&rsquo;s interest to retain, in principle, relations with the countries associated to Horizon 2020, most third countries associated to Horizon 2020 are expected to be associated to Horizon Europe with an intention to secure uninterrupted continuity between Horizon 2020 and Horizon Europe. In addition, other third countries can also become associated to Horizon Europe during the programme. For the purposes of the eligibility conditions, applicants established in Horizon 2020 Associated Countries or in other third countries negotiating association to Horizon Europe will be treated as entities established in an Associated Country, if the Horizon Europe association agreement with the third country concerned applies at the time of signature of the grant agreement<sup>[3]</sup>;</li>\r\n    <li>The following low- and middle-income countries which are constituent states of the EDCTP Association<sup>[4]</sup>: Burkina Faso, Cameroon, Congo, C&ocirc;te d&rsquo;Ivoire, Democratic Republic of the Congo, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Rwanda, Senegal, South Africa, Tanzania, Uganda, Zambia, Zimbabwe.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call conditions, or if their participation is considered essential for implementing the action by the granting authority.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Consortium composition</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of the GH EDCTP3 JU, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>At least three legal entities established in different countries, where legal entities are eligible to receive funding;</li>\r\n    <li>At least one independent legal entity established in a Member State or an associated country; and</li>\r\n    <li>At least one independent legal entity established in a sub-Saharan African (SSA) country that is a member of the EDCTP Association.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><em>Specific cases:</em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong>Affiliated entities</strong>&nbsp;&ndash; Affiliated entities are eligible for funding if they are established in one of the countries listed above.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong>International organisations</strong>&nbsp;&ndash; International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Specific rules on which legal entities can be the coordinator of an indirect action</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">According to article 110 of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe<sup>[5]</sup>, where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the financial coordinator of the indirect action shall be established in a Member State or associated country. Of the SSA countries members of the EDCTP Association, only South Africa concluded such an agreement.<sup>[6]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><strong><em><u>Scientific project leader</u></em></strong></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">If the coordinator is not established in a country in sub-Saharan Africa (SSA), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on &lsquo;scientific project leadership&rsquo; must be included in the proposals and budget needs to be provided for this activity.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:</p>\r\n<ul level=\"0\" style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">\r\n    <li>During the call for proposals and selection process, coordinate meetings on and drafting of the full project proposal;</li>\r\n    <li>Work with the coordinator and other beneficiaries on the drafting and negotiation of the consortium agreement and other legal agreements among the beneficiaries;</li>\r\n    <li>Act as the key contact point for the GH EDCTP3 regarding all scientific action governance issues, steer and provide oversight in the development of the scientific actions, acting as the key contact point for the GH EDCTP3 JU for these matters including external communication, other than the ones entrusted directly to the coordinator as per the Model Grant Agreement;</li>\r\n    <li>Support and collaborate with the coordinator on its monitoring activities and the adoption of appropriate internal measures, to ensure that beneficiaries are fulfilling their obligations regarding budget, timeline, deliverables, and scientific quality;</li>\r\n    <li>Review the action&rsquo;s deliverables and reports before their submission by the coordinator;</li>\r\n    <li>Lead the work packages(s) related to the tasks of scientific project leadership.</li>\r\n</ul>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\">Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to the GH EDCTP3 JU on all issues of interest for the proper scientific management of the action.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[1]</sup>The list is correct at the time of adoption of this work programme. Please see the Horizon Europe List of Participating Countries on the Funding &amp; Tenders Portal for up-to-date information on the current list and on the position for Associated Countries.&nbsp;<a href=\"http://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf\" style=\"color: rgb(51, 51, 51);\">https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[2]</sup>This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[3]</sup>Association of New Zealand is expected to take effect during 2023.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[4]</sup>The list is correct at the time of adoption of this work programme. For an update, please check the EDCTP Association website&nbsp;<a href=\"http://www.edctp.org/\" style=\"color: rgb(51, 51, 51);\">www.edctp.org</a>.</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[5]</sup>Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014.&nbsp;<em>OJ L 427, 30.11.2021, p. 17&ndash;119; https://eur-lex.europa.eu/eli/reg/2021/2085</em></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.718px;\"><sup>[6]</sup><a href=\"http://research-and-innovation.ec.europa.eu/strategy/strategy-2020-2024/europe-world/international-cooperation/south-africa_en\" style=\"color: rgb(51, 51, 51);\">https://research-and-innovation.ec.europa.eu/strategy/strategy-2020-2024/europe-world/international-cooperation/south-africa_en</a></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\"> described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> <span lang=\"EN-US\">of the Work Programme General Annexes</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b>4. Financial and operational capacity and exclusion: </b>described in </span></span></span><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex C</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> of the Work Programme General Annexes</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></span></span></span></p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Award criteria, scoring and      thresholds</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      D</span></span></a></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">of      the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><strong><u>Replacing relevant section in General Annex D to the Horizon Europe work programmes</u></strong></p><p><strong><em><u>Scores and weighting</u></em></strong></p><p>Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criteria 3 (Quality and efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.</p><p>Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.</p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span></span></span></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Online      Manual</span></span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex G</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span></p>\r\n<p>&nbsp;</p>\n<p>Implementing the provision on affordable access as defined in Article 114 of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe, grants awarded under this topic will have to submit the following deliverables:</p><p>1. Stewardship plan</p><p>Beneficiaries must prepare stewardship plans outlining how to achieve the optimal use of an intervention, including, for example, how to avoid irrational use, overuse, or abuse of health technologies (e.g., antimicrobials). A draft plan must be submitted after half the duration of the project has elapsed and a final plan must be submitted with the final report.</p><p>2. Global access plan</p><p>With the final report, beneficiaries must submit an appropriate and proportionate global access plan that covers registration targets, plans to meet demand, flexible approaches to IP and other strategies that reflect ability to pay and ensure that economic barriers to access are low.</p>\n<p>Also in line with Article 114 of the Council Regulation 2021/2085, participants will be subject to the following additional exploitation obligations:</p><ol level=\"0\">  <li>Participants must \u2013 up to four years after the end of the action (see Data Sheet, Point 1) \u2013 use their best efforts to ensure that resulting health technologies and services will be broadly available and accessible, as soon as possible and at fair and reasonable conditions. In this respect, if, despite a participants\u2019 best efforts, the results are not exploited within one year after the end of the action, participants must (unless otherwise agreed in writing with the granting authority) use the Horizon Results Platform to find interested parties to exploit the results.</li><li>In case the participants cannot fulfil the preceding obligation, the participants must (if requested by the granting authority) grant non-exclusive licences - under fair and reasonable conditions - to their results to legal entities that commit to rapidly and broadly exploiting the resulting health technologies and services and ensure that they are broadly available and accessible, as soon as possible and at fair and reasonable conditions.</li><li>In case of transfer of the ownership or licensing of results, participants must pass on such additional exploitation obligations to the legal entities exploiting the results.</li><li>For up to four years after the action (see Data Sheet, Point 1), the funding body must be informed every year about the status of the development of the product and any other exploitation of the results through an annual report that is due on each anniversary of the end of the grant agreement.</li> </ol>\n<h1><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\" style=\"line-height: 18.4px;\">Specific conditions</span></b></span></span><b><span lang=\"EN-US\" style=\"font-size: 12pt; line-height: 18.4px;\"><o:p></o:p></span></b></h1>\r\n<h1>\r\n<p class=\"MsoNormal\" style=\"font-size: 12px; font-weight: 400;\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">7. Specific conditions:&nbsp;</span></b><span lang=\"EN-US\">described in the specific topic of the Work Programme</span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"font-size: 12px; font-weight: 400;\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><b>Scientific Project Leader</b></span></font></p>\r\n<p class=\"MsoNormal\" style=\"font-size: 12px; font-weight: 400;\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">For all projects under this topic, if the coordinator is not established in a country in sub-Saharan Africa (SSA), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described in the introduction is mandatory. A work package on &lsquo;scientific project leadership&rsquo; must be included in the proposals and budget needs to be provided for this activity.</span></font><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><br />\r\n</span></font></p>\r\n<p class=\"MsoNormal\" style=\"font-size: 12px; font-weight: 400;\"><strong><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">Grant Conditions - EC objection to transfer of ownership to a third party in a third country</span></font></strong></p>\r\n<p class=\"MsoNormal\" style=\"font-size: 12px; font-weight: 400;\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">According to the Horizon Europe rules, and to protect Union interests, the right for the GH EDCTP3 to object to transfers of ownership of results or to grants of an exclusive licence regarding results should apply to participants. Therefore, the provisions set out in General Annex G to the Horizon Europe work programmes on the right to object apply generally. It should be noted that in accordance with the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[1] and the Model Grant Agreement, the right to object applies also to participants that have not received funding from the JU and for the periods set therein.</span></font><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\"><br />\r\n</span></font></p>\r\n<p class=\"MsoNormal\" style=\"font-size: 12px; font-weight: 400;\"><font color=\"#333333\" face=\"Helvetica Neue, Helvetica, Arial, sans-serif\"><span style=\"font-size: 13.718px;\">[1] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014; OJ L 427, 30.11.2021, p. 17</span></font></p>\r\n</h1>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p></o:p></span></p>\n<h1><span style=\"font-size: medium;\"><b><span lang=\"EN-US\" style=\"line-height: 115%;\"><span style=\"font-family: Arial;\">Documents</span></span></b></span><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\"><o:p></o:p></span></b></h1>\r\n<h1><span style=\"color: rgb(0, 0, 128);\"><font face=\"Arial\" size=\"3\">Please note that this call&nbsp;<u>is not part&nbsp;</u>of the &lsquo;blind evaluation pilot&rsquo;. Nevertheless, the standard template available on this page for the single-stage proposal is the standard template for calls that are part of this &lsquo;blind evaluation pilot&rsquo;.</font></span></h1>\r\n<h1><span style=\"color: rgb(0, 0, 128);\"><font face=\"Arial\" size=\"3\">The template for preparing the application, which is available once you press the &ldquo;start submission&rdquo; field is correct.</font></span><span style=\"color: rgb(0, 0, 128);\"><font face=\"Arial\" size=\"3\"><br />\r\n</font></span></h1>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><b><span lang=\"EN-US\">Call documents:</span></b></span></span></span><b><span lang=\"EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">Standard application form</span></span><span style=\"color: rgb(128, 128, 128);\"><span lang=\"EN-US\"> &mdash;<i style=\"mso-bidi-font-style:normal\"> call-specific application form is available in the Submission System</i></span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-ria-ia-stage-1_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Standard application form (HE RIA IA Stage 1)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span lang=\"EN-US\">Standard evaluation form</span></span><span style=\"font-size: small; color: rgb(128, 128, 128);\"><span lang=\"EN-US\"> &mdash;<i> will be used with the necessary adaptations</i></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-ria-ia-csa-stage-1_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Standard evaluation form (HE RIA, IA and CSA Stage 1)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\">MGA</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\">HE <span lang=\"EN-US\">General MGA v1.0</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"color: rgb(64, 64, 64); font-size: small;\">Call-specific instructions</span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-financial-support-to-third-parties_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on financial support to third parties (HE)</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on clinical studies (HE)</span></span></a></span></p>\n<h2><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Additional documents:</span></b></span></span></span></h2>\r\n<h2><b><span lang=\"EN-US\"><o:p></o:p></span></b></h2>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/43297f62-5b31-4375-a54a-a5d3f1b52f44_en?filename=edctp_work_programme_2023.pdf\" target=\"_blank\">Work Programme 2023</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/096afd45-ee04-4aff-9325-138ae37eaa39_en?filename=edctp_wp2023-annex1_calls_for_proposals.pdf\" target=\"_blank\">Annex 1 - Calls for proposals</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://research-and-innovation.ec.europa.eu/document/download/deb9e2bb-a8ab-48dd-b026-fc0fd4f6626b_en?filename=edctp_wp2023_annex_2_ikaa_plan.pdf\" target=\"_blank\">Annex 2 - In-kind contributions (IKAA plan)</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-g-trl_en.pdf\" target=\"_blank\">Technology readiness levels (TRL)</a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom: 0.0001pt;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-1-general-introduction_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 1. General Introduction</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-4-health_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 4. Health</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 13. General Annexes</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Programme Guide</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"font-family: Arial;\"><span style=\"font-size: small;\">HE Framework Programme and Rules for Participation Regulation 2021/695</span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\"><span style=\"font-size: small;\">HE Specific Programme Decision 2021/764</span></a></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Financial Regulation</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Grants AGA </span>&mdash; Annotated Model Grant Agreement</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Funding &amp; Tenders Portal Terms and Conditions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\" style=\"font-size: 11pt; font-family: Arial;\"><span style=\"font-size: small;\">Funding &amp; Tenders Portal Privacy Statement</span></a></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><b><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\" target=\"_blank\">Online Manual</a>&nbsp;</b></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "<p>&nbsp;<span style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">With the 2023 work programme we extend the range of topics addressed under the GH EDCTP3 JU, building on the activities launched in 2022. The work programme this year puts particular emphasis on capacity building and training. Also, for the other topics in the work programme, where relevant, support of African scientists through degree training in clinical research and/or hands on training during implementation of research projects should be provided to assist them in advancing their scientific careers. These scientists should be selected keeping gender balance in mind.</span></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">In the context of this work programme, a clinical study covers clinical studies/trials/investigations/ cohorts and is defined as any systematic prospective or retrospective collection and analysis of health data obtained from individual patients or healthy persons to address scientific questions related to the understanding, prevention, diagnosis, monitoring or treatment of a disease, mental illness, or physical condition. It includes but it is not limited to clinical studies as defined by Regulation 536/2014 (on medicinal products), clinical investigation and clinical evaluation as defined by Regulation 2017/745 (on medical devices), performance study and performance evaluation as defined by Regulation 2017/746 (on in vitro diagnostic medical devices).</p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">From 31 January 2023, all initial clinical trial applications in the European Union (EU) must be submitted via the Clinical Trials Information System (CTIS). CTIS is now the single-entry point for sponsors and regulators of clinical trials for the submission and assessment of clinical trial data. This follows a one-year transition, during which sponsors could choose whether to apply for a new clinical trial in the EU/EEA in line with the Clinical Trials Directive or under the new Clinical Trials Regulation (CTR), which entered into application on 31 January 2022.<sup>[2]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\">In the context of this work programme, FAIR data are data which meet principles of findability, accessibility, interoperability, and reusability. Data can include exploitation of information and data from European data infrastructures and programmes such as Copernicus, European Space Agency, and the GEO initiative. For further details, see the FAIR principles website<sup>[3]</sup>, the FAIR cookbook<sup>[4]</sup>&nbsp;and the guides for researchers on how to make your data FAIR.<sup>[5]</sup></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[1]</sup><a href=\"http://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf\" style=\"color: rgb(51, 51, 51);\">https://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[2]</sup><a href=\"http://www.ema.europa.eu/en/news/use-clinical-trials-information-system-becomes-mandatory-new-clinical-trial-applications-eu\" style=\"color: rgb(51, 51, 51);\">https://www.ema.europa.eu/en/news/use-clinical-trials-information-system-becomes-mandatory-new-clinical-trial-applications-eu</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[3]</sup><a href=\"http://www.go-fair.org/fair-principles/\" style=\"color: rgb(51, 51, 51);\">https://www.go-fair.org/fair-principles/</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[4]</sup><a href=\"http://faircookbook.elixir-europe.org/content/home.html\" style=\"color: rgb(51, 51, 51);\">https://faircookbook.elixir-europe.org/content/home.html</a></p>\r\n<p style=\"color: rgb(51, 51, 51); font-family: &quot;Helvetica Neue&quot;, Helvetica, Arial, sans-serif; font-size: 13.0321px;\"><sup>[5]</sup><a href=\"http://www.openaire.eu/how-to-make-your-data-fair\" style=\"color: rgb(51, 51, 51);\">https://www.openaire.eu/how-to-make-your-data-fair</a></p>", "latestInfos": [{"approvalDate": "Jul 25, 2024 9:18:51 AM", "lastChangeDate": "Jul 25, 2024 9:18:51 AM", "content": "<div>\r\n<div><u><strong>EVALUATION RESULTS STAGE 2</strong></u></div>\r\n<div>Published: 14/04/23&nbsp;</div>\r\n<div>Deadline: 28/09/23</div>\r\n<div>Available budget: 56.000.000EUR</div>\r\n<div>&nbsp;</div>\r\n<div>\r\n<div>The results of the evaluation for each topic are as follows:</div>\r\n</div>\r\n<div>\r\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"479\" style=\"border-collapse:&#10; collapse;width:360pt\">\r\n    <colgroup><col width=\"252\" style=\"mso-width-source:userset;mso-width-alt:8797;width:189pt\" />  <col width=\"116\" style=\"mso-width-source:userset;mso-width-alt:4049;width:87pt\" />  <col width=\"111\" style=\"mso-width-source:userset;mso-width-alt:3886;width:84pt\" />  </colgroup>\r\n    <tbody>\r\n        <tr height=\"50\" style=\"height:37.5pt\">\r\n            <td height=\"50\" class=\"xl65\" width=\"252\" style=\"height: 37.5pt; width: 189pt; text-align: center;\">&nbsp;</td>\r\n            <td class=\"xl66\" width=\"116\" style=\"border-left: none; width: 87pt; text-align: center;\">HORIZON-JU-GH-EDCTP3-2023-02-01-two-stage</td>\r\n            <td class=\"xl66\" width=\"111\" style=\"border-left: none; width: 84pt; text-align: center;\">HORIZON-JU-GH-EDCTP3-2023-02-02-two-stage</td>\r\n        </tr>\r\n        <tr height=\"50\" style=\"height:37.5pt\">\r\n            <td height=\"50\" class=\"xl67\" width=\"252\" style=\"height: 37.5pt; border-top: none; width: 189pt; text-align: center;\">Number of proposals submitted (including proposals transferred   from or to other calls)</td>\r\n            <td class=\"xl68\" width=\"116\" style=\"border-top: none; border-left: none; width: 87pt; text-align: center;\">15</td>\r\n            <td class=\"xl68\" width=\"111\" style=\"border-top: none; border-left: none; width: 84pt; text-align: center;\">21</td>\r\n        </tr>\r\n        <tr height=\"17\" style=\"height:12.5pt\">\r\n            <td height=\"17\" class=\"xl67\" width=\"252\" style=\"height: 12.5pt; border-top: none; width: 189pt; text-align: center;\">Number of inadmissible proposals</td>\r\n            <td class=\"xl68\" width=\"116\" style=\"border-top: none; border-left: none; width: 87pt; text-align: center;\">0</td>\r\n            <td class=\"xl68\" width=\"111\" style=\"border-top: none; border-left: none; width: 84pt; text-align: center;\">0</td>\r\n        </tr>\r\n        <tr height=\"17\" style=\"height:12.5pt\">\r\n            <td height=\"17\" class=\"xl67\" width=\"252\" style=\"height: 12.5pt; border-top: none; width: 189pt; text-align: center;\">Number of ineligible proposals</td>\r\n            <td class=\"xl68\" width=\"116\" style=\"border-top: none; border-left: none; width: 87pt; text-align: center;\">0</td>\r\n            <td class=\"xl68\" width=\"111\" style=\"border-top: none; border-left: none; width: 84pt; text-align: center;\">0</td>\r\n        </tr>\r\n        <tr height=\"17\" style=\"height:12.5pt\">\r\n            <td height=\"17\" class=\"xl67\" width=\"252\" style=\"height: 12.5pt; border-top: none; width: 189pt; text-align: center;\">Number of above-threshold proposals</td>\r\n            <td class=\"xl68\" width=\"116\" style=\"border-top: none; border-left: none; width: 87pt; text-align: center;\">8</td>\r\n            <td class=\"xl68\" width=\"111\" style=\"border-top: none; border-left: none; width: 84pt; text-align: center;\">17</td>\r\n        </tr>\r\n        <tr height=\"33\" style=\"height:25.0pt\">\r\n            <td height=\"33\" class=\"xl67\" width=\"252\" style=\"height: 25pt; border-top: none; width: 189pt; text-align: center;\">Total budget requested for above-threshold proposals</td>\r\n            <td class=\"xl69\" width=\"116\" style=\"border-top: none; border-left: none; width: 87pt; text-align: center;\">41.921.200</td>\r\n            <td class=\"xl69\" width=\"111\" style=\"border-top: none; border-left: none; width: 84pt; text-align: center;\">80.967.544</td>\r\n        </tr>\r\n        <tr height=\"17\" style=\"height:12.5pt\">\r\n            <td height=\"17\" class=\"xl67\" width=\"252\" style=\"height: 12.5pt; border-top: none; width: 189pt; text-align: center;\">Number of proposals retained for funding</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">5</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">5</td>\r\n        </tr>\r\n        <tr height=\"17\" style=\"height:12.5pt\">\r\n            <td height=\"17\" class=\"xl67\" width=\"252\" style=\"height: 12.5pt; border-top: none; width: 189pt; text-align: center;\">Number of proposals in the reserve list</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">3</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">3</td>\r\n        </tr>\r\n        <tr height=\"17\" style=\"height:12.5pt\">\r\n            <td height=\"17\" class=\"xl67\" width=\"252\" style=\"height: 12.5pt; border-top: none; width: 189pt; text-align: center;\">Funding threshold</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">13</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">13,5*</td>\r\n        </tr>\r\n        <tr height=\"33\" style=\"height:25.0pt\">\r\n            <td height=\"33\" class=\"xl67\" width=\"252\" style=\"height: 25pt; border-top: none; width: 189pt; text-align: center;\">Number of proposals with scores lower or equal to 15 and higher   or equal to 14</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">3</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">4</td>\r\n        </tr>\r\n        <tr height=\"33\" style=\"height:25.0pt\">\r\n            <td height=\"33\" class=\"xl67\" width=\"252\" style=\"height: 25pt; border-top: none; width: 189pt; text-align: center;\">Number of proposals with scores lower than 14 and higher or   equal to 13</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">2</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">6</td>\r\n        </tr>\r\n        <tr height=\"33\" style=\"height:25.0pt\">\r\n            <td height=\"33\" class=\"xl67\" width=\"252\" style=\"height: 25pt; border-top: none; width: 189pt; text-align: center;\">Number of proposals with scores lower than 13 and higher or   equal to 10</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">3</td>\r\n            <td class=\"xl70\" style=\"border-top: none; border-left: none; text-align: center;\">7</td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<p>*Proposals with the same score were ranked according to the priority order procedure set out in the General Annexes to the Work Programme or specific arrangements in the specific call/topic conditions.</p>\r\n<p>&nbsp;</p>\r\n<p>Summary of observer report:</p>\r\n<p><em>During the period of observation, the Independent Observer followed remotely the compilation of the IERs by the individual experts, the compilation of draft CR by rapporteurs, the feedback being provided by the individual experts within SEP, followed a sample of full consensus meetings and panel meetings. During this assessment IO noted that the proceedings of the evaluation were open, transparent and professionally conducted, ensuring that the outcome was of very high quality. Thus, the main observations can be summarised as follows:</em></p>\r\n<p><em>a) The evaluation was open, fair and rigorous and in accordance with the relevant rules and established procedures.</em></p>\r\n<p><em>b) Consensus Meetings (CMs) and Panel Meetings (PMs) were professionally conducted and throughout the process, overall moved smoothly, without any major issues</em></p>\r\n<p><em>Some recommendations for consideration on improving the evaluation process have been suggested, where applicable.</em></p>\r\n<div>&nbsp;</div>\r\n</div>\r\n<div>We recently informed the applicants about the evaluation results for their proposals.&nbsp;</div>\r\n<div>For questions, please contact EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu</div>\r\n</div>"}, {"approvalDate": "Dec 20, 2023 3:21:27 PM", "lastChangeDate": "Dec 20, 2023 3:21:27 PM", "content": "<div>\r\n<div><u><strong>EVALUATION RESULTS STAGE 1</strong></u></div>\r\n<div>Published: 14/04/23&nbsp;</div>\r\n<div>Deadline: 28/09/23</div>\r\n<div>Available budget: 56.000.000EUR</div>\r\n<div>&nbsp;</div>\r\n<div>In accordance with the call conditions, the evaluation of the first-stage proposals was made looking only at the criteria 'Excellence' and 'Impact'. The threshold for both criteria was 4. The overall threshold (applying to the sum of the two individual scores) was set for each topic/type of action with separate call-budget-split at a level that allowed the total requested budget of proposals admitted to stage 2 be as close as possible to 3 times the available budget (and not below 2.5 times the budget):</div>\r\n<ul>\r\n    <li>HORIZON-JU-GH-EDCTP3-2023-02-01-two-stage: <strong>8</strong> points</li>\r\n    <li>HORIZON-JU-GH-EDCTP3-2023-02-02-two-stage: <strong>9</strong> points</li>\r\n</ul>\r\n<div>The results of the evaluation are as follows :&nbsp;</div>\r\n<ul>\r\n    <li>Number of proposals submitted (including proposals transferred from or to other calls): 79</li>\r\n    <li>Number of ineligible proposals: 5</li>\r\n    <li>Number of above-threshold proposals: 37</li>\r\n    <li>Total budget requested for above-threshold proposals: 180.986.064</li>\r\n</ul>\r\n<div>We recently informed the applicants about the evaluation results for their proposals.&nbsp;</div>\r\n<div>For questions, please contact EC-GLOBAL-HEALTH-EDCTP3@ec.europa.eu</div>\r\n</div>"}, {"approvalDate": "Oct 3, 2023 3:41:00 PM", "lastChangeDate": "Oct 3, 2023 3:41:00 PM", "content": "<div>Call HORIZON-JU-GH-EDCTP3-2023-02-two-stage has closed on September 28th, 2023.</div>\r\n<div>79 proposals have been submitted.</div>\r\n<div>The breakdown per topic is:</div>\r\n<ul>\r\n    <li>HORIZON-JU-GH-EDCTP3-2023-02-01-two-stage: 28 proposals</li>\r\n    <li>HORIZON-JU-GH-EDCTP3-2023-02-02-two-stage: 51 proposals</li>\r\n</ul>\r\n<div>Evaluation results are expected to be communicated in January 2024</div>"}, {"approvalDate": "Jun 27, 2023 12:00:01 AM", "lastChangeDate": "Jun 27, 2023 12:00:01 AM", "content": "The submission session is now available for: HORIZON-JU-GH-EDCTP3-2023-02-01-two-stage(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2023-02-02-two-stage(HORIZON-JU-RIA)"}, {"approvalDate": "Jun 13, 2023 10:39:14 AM", "lastChangeDate": "Jun 13, 2023 10:39:14 AM", "content": "<p>&nbsp;<span lang=\"EN-US\" style=\"font-size:11.0pt;font-family:&#10;&quot;Calibri&quot;,sans-serif;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:&#10;AR-SA\">The 2<sup>nd</sup> stage deadline has been postponed to 03/04/2024</span></p>"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}